Saturday, June 29, 2013

Oracle Offers Cloud Services to Streamline Pharmacovigilance for Life Sciences Industry

Helps trial sponsors and contract research organizations to manage safety and pharmacovigilance programs on Cloud 

Kuala Lumpur, 27 June 2013 - Oracle Corporation (NASDAQ: ORCL), the world's leading IT solution provider, today unveils Oracle Argus Cloud Service for life sciences organization to monitor and deliver new insight into adverse events and pharmacovigilance programs.

The new offering is delivered via the Oracle Health Sciences Cloud and enables health sciences organizations to optimize their safety investment while reducing IT management resource requirements and infrastructure costs and gaining more predictable IT spend.

Oracle Argus Cloud Service includes expanded analytical and reporting capabilities that help to integrate safety and risk management:  

Oracle Argus Analytics provides study sponsors and clinical research organizations with fact-based insight into safety data collection and case processing to help boost productivity and reduce costs.

Oracle Argus Insight enables study sponsors and medical reviewers to carefully analyze pharmaceutical safety data and make business decisions quickly and confidently.

In addition, the cloud-based version of Oracle’s leading integrated global adverse events management and regulatory reporting suite now includes Oracle Argus Japan. This addition creates a single global database for safety data, including data from Japan, and enables a unified workflow and reporting environment designed to improve process efficiency and expand visibility.  

“Oracle Argus Cloud Service delivers extended value to health sciences organizations with the addition of Oracle Argus Japan, Oracle Argus Analytics and Oracle Argus Insight. Trial sponsors and contract research organizations can manage their end-to-end safety and pharmacovigilance programs with a leading solution suite while benefitting from a cloud-based delivery model that helps accelerate time to value, reduce risk, cut total cost of IT ownership and that provides unprecedented performance and scalability,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences.

No comments: